Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes - Related Studies

Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes (AZALE)

This study is currently recruiting participants.

Verified June 2011 by Dresden University of Technology

Study NCT00923234 Information provided by Dresden University of Technology

First Received on June 17, 2009. Last Updated on June 24, 2011 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Myelodysplastic Syndromes
Acute Myelogenous Leukemia

Additional conditions recognized in this trial

Chromosome Aberrations
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Preleukemia

More general conditions related to this trial

Bone Marrow Diseases
Hematologic Diseases
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Precancerous Conditions

Interventions listed in this trial

Azacitidine
Lenalidomide

Additional drug interventions recognized in this trial

Thalidomide

More general drug interventions related to this trial

Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

Sponsors listed in this trial

Dresden University of Technology
Celgene Corporation